Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer

BACKGROUND: Three different tyrosine kinase inhibitors have been approved as first-line therapies for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer with similar overall survival. This study determined dynamic changes in quality of life (QoL) for patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Szu-Chun, Lin, Chien-Chung, Lai, Wu-Wei, Chang, Sheng-Mao, Hwang, Jing-Shiang, Su, Wu-Chou, Wang, Jung-Der
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802707/
https://www.ncbi.nlm.nih.gov/pubmed/29434678
http://dx.doi.org/10.1177/1758834018755072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802707/
https://www.ncbi.nlm.nih.gov/pubmed/29434678
http://dx.doi.org/10.1177/1758834018755072

Ejemplares similares